DK1345895T3 - Hidtil ukendt diphenylazetidioner, fremgangsmåde til deres fremstilling, lægemidler indeholdende disse forbindelser og deres anvendelse til behandling af lipidstofskifteforstyrrelser - Google Patents

Hidtil ukendt diphenylazetidioner, fremgangsmåde til deres fremstilling, lægemidler indeholdende disse forbindelser og deres anvendelse til behandling af lipidstofskifteforstyrrelser

Info

Publication number
DK1345895T3
DK1345895T3 DK01271353T DK01271353T DK1345895T3 DK 1345895 T3 DK1345895 T3 DK 1345895T3 DK 01271353 T DK01271353 T DK 01271353T DK 01271353 T DK01271353 T DK 01271353T DK 1345895 T3 DK1345895 T3 DK 1345895T3
Authority
DK
Denmark
Prior art keywords
diphenylazetid
hitherto
ions
compounds
preparation
Prior art date
Application number
DK01271353T
Other languages
Danish (da)
English (en)
Inventor
Stefanie Flohr
Heiner Glombik
Werner Kramer
Wendelin Frick
Hubert Heuer
Gerhard Jaehne
Andreas Lindenschmidt
Hans-Ludwig Schaefer
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26008042&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1345895(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE10064398A external-priority patent/DE10064398A1/de
Priority claimed from DE2001152981 external-priority patent/DE10152981A1/de
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Application granted granted Critical
Publication of DK1345895T3 publication Critical patent/DK1345895T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK01271353T 2000-12-21 2001-12-11 Hidtil ukendt diphenylazetidioner, fremgangsmåde til deres fremstilling, lægemidler indeholdende disse forbindelser og deres anvendelse til behandling af lipidstofskifteforstyrrelser DK1345895T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10064398A DE10064398A1 (de) 2000-12-21 2000-12-21 Neue Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
DE2001152981 DE10152981A1 (de) 2001-10-26 2001-10-26 Neue Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
PCT/EP2001/014531 WO2002050027A1 (de) 2000-12-21 2001-12-11 Neue diphenzylazetidinone, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung zur behandlung von lipidstoffwechselstörungen

Publications (1)

Publication Number Publication Date
DK1345895T3 true DK1345895T3 (da) 2007-05-07

Family

ID=26008042

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01271353T DK1345895T3 (da) 2000-12-21 2001-12-11 Hidtil ukendt diphenylazetidioner, fremgangsmåde til deres fremstilling, lægemidler indeholdende disse forbindelser og deres anvendelse til behandling af lipidstofskifteforstyrrelser

Country Status (29)

Country Link
US (5) US6992067B2 (et)
EP (1) EP1345895B1 (et)
JP (1) JP4605990B2 (et)
KR (1) KR100833089B1 (et)
CN (1) CN1217927C (et)
AR (1) AR034010A1 (et)
AT (1) ATE349425T1 (et)
AU (2) AU2002216097B2 (et)
BR (1) BR0116325A (et)
CA (1) CA2431983C (et)
CY (1) CY1106383T1 (et)
CZ (1) CZ20031732A3 (et)
DE (1) DE50111751D1 (et)
DK (1) DK1345895T3 (et)
EE (1) EE200300236A (et)
ES (1) ES2277890T3 (et)
HK (1) HK1060120A1 (et)
HR (1) HRP20030498A2 (et)
HU (1) HUP0401081A3 (et)
IL (2) IL156550A0 (et)
MX (1) MXPA03005155A (et)
NO (1) NO325496B1 (et)
NZ (1) NZ526593A (et)
PL (1) PL362379A1 (et)
PT (1) PT1345895E (et)
RS (1) RS50864B (et)
SK (1) SK7822003A3 (et)
TW (1) TWI293626B (et)
WO (1) WO2002050027A1 (et)

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6584357B1 (en) * 2000-10-17 2003-06-24 Sony Corporation Method and system for forming an acoustic signal from neural timing difference data
ATE349425T1 (de) * 2000-12-21 2007-01-15 Sanofi Aventis Deutschland Neue diphenzylazetidinone, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung zur behandlung von lipidstoffwechselstörungen
US20020147184A1 (en) * 2001-01-26 2002-10-10 Schering Corporation Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions
TW200840563A (en) * 2001-01-26 2008-10-16 Schering Corp Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(S) and treatments for vascular indications
WO2002058731A2 (en) * 2001-01-26 2002-08-01 Schering Corporation Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions
DE60216890T2 (de) * 2001-01-26 2007-08-30 Schering Corp. Kombinationen von einem hemmer der sterol-absorption und einem ppar-aktivator zur behandlung von kardiovaskulären indikationen
WO2002058733A2 (en) * 2001-01-26 2002-08-01 Schering Corporation Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications
BRPI0208384B1 (pt) 2001-03-28 2016-05-31 Merck Sharp & Dohme síntese enantiosseletiva de compostos intermediários de azetidinona
US20030119808A1 (en) * 2001-09-21 2003-06-26 Schering Corporation Methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects
ATE345793T1 (de) * 2001-09-21 2006-12-15 Schering Corp Behandlung von xanthom mittels azetidinon- derivate als hemmer der sterol absorption
US7053080B2 (en) * 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US20030204096A1 (en) * 2002-03-25 2003-10-30 Schering Corporation Enantioselective synthesis of azetidinone intermediate compounds
DE10227508A1 (de) * 2002-06-19 2004-01-08 Aventis Pharma Deutschland Gmbh Säuregruppen-substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
US7671047B2 (en) 2002-06-19 2010-03-02 Sanofi-Aventis Deutschland Gmbh Cationically substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
DE10227507A1 (de) * 2002-06-19 2004-01-08 Aventis Pharma Deutschland Gmbh Kationisch substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
US7176193B2 (en) 2002-06-19 2007-02-13 Sanofi-Aventis Deutschland Gmbh Acid-group-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
US7176194B2 (en) 2002-06-19 2007-02-13 Sanofi-Aventis Deutschland Gmbh Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
GB0215579D0 (en) * 2002-07-05 2002-08-14 Astrazeneca Ab Chemical compounds
DE10308353A1 (de) 2003-02-27 2004-12-02 Aventis Pharma Deutschland Gmbh Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE10308351A1 (de) 2003-02-27 2004-11-25 Aventis Pharma Deutschland Gmbh 1,3-substituierte Cycloalkylderivate mit sauren, meist heterocyclischen Gruppen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE10308352A1 (de) 2003-02-27 2004-09-09 Aventis Pharma Deutschland Gmbh Arylcycloalkylderivate mit verzweigten Seitenketten, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
US7148246B2 (en) 2003-02-27 2006-12-12 Sanofi-Aventis Deutschland Gmbh Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals
DE10308355A1 (de) 2003-02-27 2004-12-23 Aventis Pharma Deutschland Gmbh Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
US7208486B2 (en) 2003-03-07 2007-04-24 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7459442B2 (en) * 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7235543B2 (en) 2003-03-07 2007-06-26 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
DE10314610A1 (de) * 2003-04-01 2004-11-04 Aventis Pharma Deutschland Gmbh Neues Diphenylazetidinon mit verbesserten physiologischen Eigenschaften, Verfahren zu dessen Herstellung, diese Verbindungen enthaltende Arzneimittel und dessen Verwendung
EP1682117A1 (en) * 2003-10-30 2006-07-26 Merck & Co., Inc. 2-azetidinones as anti-hypercholesterolemic agents
EP1918000A2 (en) 2003-11-05 2008-05-07 Schering Corporation Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
EP1832576A1 (en) * 2003-11-10 2007-09-12 Microbia Inc. 4-Biarylyl-1-phenolyzetidin-2-ones
WO2005047248A1 (en) 2003-11-10 2005-05-26 Microbia, Inc. 4-biarylyl-1-phenylazetidin-2-ones
RU2422450C2 (ru) 2003-11-19 2011-06-27 Метабазис Терапеутикс, Инк. Новые фосфорсодержащие тиромиметики
CN100471835C (zh) * 2003-12-23 2009-03-25 默克公司 抗高胆固醇血症化合物
SA04250427A (ar) 2003-12-23 2005-12-03 استرازينيكا ايه بي مشتقات ثاني فينيل أزيتيدون
US7241787B2 (en) 2004-01-25 2007-07-10 Sanofi-Aventis Deutschland Gmbh Substituted N-cycloexylimidazolinones, process for their preparation and their use as medicaments
EP1586573B1 (en) 2004-04-01 2007-02-07 Sanofi-Aventis Deutschland GmbH Oxadiazolones, processes for their preparation and their use as pharmaceuticals
MXPA06013456A (es) 2004-05-21 2007-03-01 Sanofi Aventis Deutschland Metodo para producir derivados de 1,4-difenilazetidinona.
DOP2005000123A (es) * 2004-07-02 2011-07-15 Merck Sharp & Dohme Inhibidores de cetp
EP1807070A1 (en) * 2004-09-29 2007-07-18 Schering Corporation Combinations of substituted azetidinones and cb1 antagonists
SG163577A1 (en) 2004-12-03 2010-08-30 Schering Corp Substituted piperazines as cb1 antagonists
EP1831162B1 (en) 2004-12-20 2012-10-31 Merck Sharp & Dohme Corp. Process for the synthesis of azetidinones
TW200726746A (en) * 2005-05-06 2007-07-16 Microbia Inc Processes for production of 4-biphenylylazetidin-2-ones
CA2608075A1 (en) * 2005-05-11 2006-11-16 Microbia, Inc. Processes for production of phenolic 4-biphenylylazetidin-2-ones
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
EP1896135A2 (en) * 2005-05-25 2008-03-12 Microbia, Inc. Processes for production of 4-(biphenylyl)azetidin-2-one phosphonic acids
DE102005026762A1 (de) 2005-06-09 2006-12-21 Sanofi-Aventis Deutschland Gmbh Azolopyridin-2-on-derivate als Inhibitoren von Lipasen und Phospholipasen
CA2611142A1 (en) * 2005-06-15 2006-12-28 Merck & Co., Inc. Anti-hypercholesterolemic compounds
MX2008000115A (es) * 2005-06-20 2008-03-18 Schering Corp Derivados de piperidina utiles como antagonistas de histamina h3.
SA06270191B1 (ar) 2005-06-22 2010-03-29 استرازينيكا ايه بي مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
TW200806623A (en) * 2005-10-05 2008-02-01 Merck & Co Inc Anti-hypercholesterolemic compounds
CA2634940A1 (en) * 2005-12-21 2007-07-05 Schering Corporation Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and h3 receptor antagonist/inverse agonist
CA2637565A1 (en) * 2006-01-18 2007-07-26 Schering Corporation Cannibinoid receptor modulators
TW200811098A (en) 2006-04-27 2008-03-01 Astrazeneca Ab Chemical compounds
JP2010500300A (ja) 2006-08-08 2010-01-07 サノフィ−アベンティス アリールアミノアリール−アルキル−置換イミダゾリジン−２，４−ジオン、それらの製造法、それらの化合物を含有する薬剤、およびそれらの使用
CA2661404A1 (en) * 2006-09-05 2008-03-13 Schering Corporation Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis
US7638526B2 (en) * 2006-09-15 2009-12-29 Schering Corporation Azetidine derivatives useful in treating pain, diabetes and disorders of lipid metabolism
EP2061792A2 (en) * 2006-09-15 2009-05-27 Schering Corporation Azetidinone derivatives for the treatment of disorders of the lipid metabolism
MX2009002922A (es) 2006-09-15 2009-04-01 Schering Corp Derivados de azetidina y azetidona utiles en el tratamiento del dolor y de trastornos del metabolismo lipidico.
JP2010503672A (ja) * 2006-09-15 2010-02-04 シェーリング コーポレイション 脂質代謝障害、疼痛、糖尿病、および他の障害を治療するためのスピロ環アゼチジノン誘導体
JP2010509216A (ja) * 2006-11-02 2010-03-25 メルク エンド カムパニー インコーポレーテッド ヘテロシクリル置換抗高コレステロール血症化合物
WO2008130616A2 (en) * 2007-04-19 2008-10-30 Schering Corporation Diaryl morpholines as cb1 modulators
US20080319218A1 (en) * 2007-06-22 2008-12-25 Andreas Haubrich Processes for Making and Using Benzyl Pentahydroxyhexylcarbamoylundecanoate
DE102007029612A1 (de) 2007-06-27 2009-01-08 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von Pentahydroxyhexylcarbamoylundekan- säurebenzylester
US20080319221A1 (en) * 2007-06-22 2008-12-25 Bernd Junker Esters of Pentahydroxyhexylcarbamoyl Alkanoic Acids
JP2010531874A (ja) * 2007-06-28 2010-09-30 インターベット インターナショナル ベー． フェー． Ｃｂ１アンタゴニストとしての置換ピペラジン
KR20100051625A (ko) * 2007-06-28 2010-05-17 인터벳 인터내셔널 비.브이. Ｃｂ1 길항제로서의 치환된 피페라진
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102007063671A1 (de) 2007-11-13 2009-06-25 Sanofi-Aventis Deutschland Gmbh Neue kristalline Diphenylazetidinonhydrate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
WO2009097995A1 (de) * 2008-02-07 2009-08-13 Sanofi-Aventis Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
SG171985A1 (en) 2008-12-11 2011-07-28 Agency For Science Techonology And Res Glucose-peg conjugates for reducing glucose transport into a cell
EP2379562A1 (en) 2008-12-16 2011-10-26 Schering Corporation Bicyclic pyranone derivatives as nicotinic acid receptor agonists
US20110245209A1 (en) 2008-12-16 2011-10-06 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
US20120046364A1 (en) 2009-02-10 2012-02-23 Metabasis Therapeutics, Inc. Novel Sulfonic Acid-Containing Thyromimetics, and Methods for Their Use
CA2754384A1 (en) 2009-03-06 2010-09-10 Lipideon Biotechnology Ag Pharmaceutical hypocholesterolemic compositions
US9388440B2 (en) 2009-04-01 2016-07-12 Mylan Laboratories Limited Enzymatic process for the preparation of (S)-5-(4-fluoro-phenyl)-5-hydroxy-1morpholin-4-yl-pentan-1-one, an intermediate of Ezetimibe and further conversion to Ezetimibe
CN101993403B (zh) * 2009-08-11 2012-07-11 浙江海正药业股份有限公司 氮杂环丁酮类化合物及医药应用
DE102010015123A1 (de) 2010-04-16 2011-10-20 Sanofi-Aventis Deutschland Gmbh Benzylamidische Diphenylazetidinone, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
EP2566497B1 (en) 2010-05-04 2015-07-29 Codexis, Inc. Biocatalysts for ezetimibe synthesis
ES2552657T3 (es) 2010-05-26 2015-12-01 Satiogen Pharmaceuticals, Inc. Inhibidores del reciclado de ácidos biliares y saciógenos para el tratamiento de diabetes, obesidad, y afecciones gastrointestinales inflamatorias
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
ES2372460B1 (es) * 2010-07-09 2012-11-16 Moehs Ibérica S.L. Nuevo método para la preparación de ezetimiba.
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120051A1 (de) 2011-03-08 2012-09-13 Sanofi Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120050A1 (de) 2011-03-08 2012-09-13 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683700B1 (de) 2011-03-08 2015-02-18 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683705B1 (de) 2011-03-08 2015-04-22 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683701B1 (de) 2011-03-08 2014-12-24 Sanofi Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120057A1 (de) 2011-03-08 2012-09-13 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
CN102219803B (zh) * 2011-04-20 2013-07-31 浙江大学 一种伊替米贝中间体的制备方法
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
PL2771003T3 (pl) 2011-10-28 2017-10-31 Lumena Pharmaceuticals Llc Inhibitory ponownego wykorzystania kwasów żółciowych do leczenia pediatrycznych cholestatycznych chorób wątroby
US20140323412A1 (en) 2011-10-28 2014-10-30 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of hypercholemia and cholestatic liver disease
CN102746249B (zh) * 2012-07-07 2013-12-25 山东诚创医药技术开发有限公司 一种依折麦布中间体的纯化精制方法
KR20230152818A (ko) 2013-03-15 2023-11-03 샤이어 휴먼 지네틱 테라피즈 인크. 원발성 담관염 및 염증성 장 질환 치료용 담즙산 재순환 억제제
BR112015023697A2 (pt) 2013-03-15 2017-07-18 Lumena Pharmaceuticals Inc inibidores de ácidos biliares de reciclagem para tratamento de esôfago de barrett e doença do refluxo gastroesofágico
CN104513187B (zh) * 2015-01-09 2017-05-31 安润医药科技（苏州）有限公司 依折麦布及其中间体的合成方法
BR112021015799A2 (pt) 2019-02-12 2022-01-18 Mirum Pharmaceuticals Inc Métodos para aumentar o crescimento em pacientes pediátricos com doença colestática do fígado
US11504390B2 (en) 2019-03-20 2022-11-22 Regeneron Pharmaceuticals, Inc. Treatment of increased lipid levels with sterol regulatory element binding transcription factor 1 (SREBF1) inhibitors
US11331332B2 (en) 2019-03-20 2022-05-17 Regeneron Pharmaceuticals, Inc. Treatment of increased lipid levels with sterol regulatory element binding protein cleavage-activating protein (SCAP) inhibitors

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5631365A (en) * 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US5656624A (en) * 1994-12-21 1997-08-12 Schering Corporation 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents
BR9612998B1 (pt) * 1995-10-31 2010-03-23 2-azetidinonas substituÍdas com aÇécar éteis como agentes hipocolesterolÊmicos, composiÇço farmacÊutica e kit contendo as mesmas.
US6225310B1 (en) 1996-01-17 2001-05-01 Novo Nordisk A/S Fused 1,2,4-thiadiazine derivatives, their preparation and use
CN1158290C (zh) 1996-01-17 2004-07-21 诺沃挪第克公司 稠合1,2,4-噻二嗪与稠合1,4-噻嗪衍生物、其制备方法及用途
CN1110494C (zh) * 1996-03-11 2003-06-04 G·D·瑟尔公司 具有作为回肠胆汁酸转运和牛磺胆酸盐吸收抑制剂活性的新的苯并噻庚因
US5739321A (en) * 1996-05-31 1998-04-14 Schering Corporation 3-hydroxy γ-lactone based enantionselective synthesis of azetidinones
WO1997041097A2 (en) 1996-12-31 1997-11-06 Dr. Reddy's Research Foundation Novel heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
BRPI9711437B8 (pt) 1996-08-30 2021-05-25 Novo Nordisk As derivados de glp-1
US5756470A (en) * 1996-10-29 1998-05-26 Schering Corporation Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
BR9810592A (pt) 1997-07-16 2000-09-12 Novo Nordisk As Composto, processos para preparar um composto, para tratar ou prevenir doenças do sistema endócrino e para a fabricação de um medicamento, composição farmacêutica, e, uso de um composto
DE19825804C2 (de) * 1998-06-10 2000-08-24 Aventis Pharma Gmbh 1,4-Benzothiepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
DE19845405C2 (de) * 1998-10-02 2000-07-13 Aventis Pharma Gmbh Arylsubstituierte Propanolaminderivate und deren Verwendung
DE19916108C1 (de) * 1999-04-09 2001-01-11 Aventis Pharma Gmbh Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung
WO2000063703A1 (en) * 1999-04-16 2000-10-26 Schering Corporation Use of azetidinone compounds
AU2001277056B2 (en) 2000-07-25 2005-09-29 Merck & Co., Inc. N-substituted indoles useful in the treatment of diabetes
ATE349425T1 (de) * 2000-12-21 2007-01-15 Sanofi Aventis Deutschland Neue diphenzylazetidinone, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung zur behandlung von lipidstoffwechselstörungen
IL156552A0 (en) * 2000-12-21 2004-01-04 Aventis Pharma Gmbh Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use
US7176194B2 (en) * 2002-06-19 2007-02-13 Sanofi-Aventis Deutschland Gmbh Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
US7176193B2 (en) * 2002-06-19 2007-02-13 Sanofi-Aventis Deutschland Gmbh Acid-group-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
US7671047B2 (en) * 2002-06-19 2010-03-02 Sanofi-Aventis Deutschland Gmbh Cationically substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
DE10314610A1 (de) * 2003-04-01 2004-11-04 Aventis Pharma Deutschland Gmbh Neues Diphenylazetidinon mit verbesserten physiologischen Eigenschaften, Verfahren zu dessen Herstellung, diese Verbindungen enthaltende Arzneimittel und dessen Verwendung
DE102004025072A1 (de) * 2004-05-21 2005-12-15 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von Diphenyl-azetidinon-Derivaten
DE102005055726A1 (de) * 2005-11-23 2007-08-30 Sanofi-Aventis Deutschland Gmbh Hydroxy-substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung

Also Published As

Publication number Publication date
BR0116325A (pt) 2003-10-14
HUP0401081A2 (hu) 2004-09-28
HK1060120A1 (en) 2004-07-30
US20050267038A1 (en) 2005-12-01
CA2431983A1 (en) 2002-06-27
NO20032734L (no) 2003-08-18
EP1345895B1 (de) 2006-12-27
TWI293626B (en) 2008-02-21
US6992067B2 (en) 2006-01-31
CZ20031732A3 (cs) 2003-09-17
US20070208179A1 (en) 2007-09-06
SK7822003A3 (en) 2003-12-02
YU45403A (sh) 2006-05-25
JP4605990B2 (ja) 2011-01-05
IL156550A0 (en) 2004-01-04
PL362379A1 (en) 2004-10-18
EE200300236A (et) 2003-08-15
AR034010A1 (es) 2004-01-21
DE50111751D1 (de) 2007-02-08
CA2431983C (en) 2010-06-08
NZ526593A (en) 2005-02-25
AU2002216097B2 (en) 2006-09-07
CY1106383T1 (el) 2011-10-12
WO2002050027A1 (de) 2002-06-27
MXPA03005155A (es) 2003-09-10
US20100160282A1 (en) 2010-06-24
CN1483021A (zh) 2004-03-17
ES2277890T3 (es) 2007-08-01
HRP20030498A2 (en) 2005-04-30
US7674773B2 (en) 2010-03-09
US20080281092A1 (en) 2008-11-13
KR100833089B1 (ko) 2008-05-29
US7488829B2 (en) 2009-02-10
RS50864B (sr) 2010-08-31
JP2004516280A (ja) 2004-06-03
KR20030061460A (ko) 2003-07-18
AU1609702A (en) 2002-07-01
EP1345895A1 (de) 2003-09-24
ATE349425T1 (de) 2007-01-15
US7576200B2 (en) 2009-08-18
NO325496B1 (no) 2008-05-19
HUP0401081A3 (en) 2010-06-28
PT1345895E (pt) 2007-02-28
NO20032734D0 (no) 2003-06-16
CN1217927C (zh) 2005-09-07
US20020137689A1 (en) 2002-09-26
IL156550A (en) 2009-08-03

Similar Documents

Publication Publication Date Title
DK1345895T3 (da) Hidtil ukendt diphenylazetidioner, fremgangsmåde til deres fremstilling, lægemidler indeholdende disse forbindelser og deres anvendelse til behandling af lipidstofskifteforstyrrelser
NO20032733L (no) Difenylazetidinonderivater, fremgangsmåte for deres fremstilling, legemidler som inneholder disse forbindelsene og deres anvendelse
NO20032726L (no) Kinazolinderivater, medikamenter inneholdende disse forbindelser, deres anvendelse og fremgangsmåte for fremstilling derav
EE05149B1 (et) Biarlkarboksamiidid, meetod nende valmistamiseks, neid sisaldav ravimkoostis ning nende kasutamine ravis
DK1183029T3 (da) Farmaceutisk præparat indeholdende diamorfin og vitamin E og dets anvendelse til behandling af opiatmisbrug
DK1112251T3 (da) Azetidinderivater, deres fremstilling og medikamenter indeholdende disse derivater
NO20030870D0 (no) Bicykliske heterocykler, medikamenter inneholdende disse, deres anvendelseog fremgansgmåte for fremstilling derav
IS6560A (is) Lyfjasamsetning fyrir meðhöndlun á bráðum, þrálátum sársauka og/eða taugakerfissársauka og mígreni
NO20011964D0 (no) Brönnbehandlingsfluider og fremgangsmåter med anvendelse derav
NO20032735L (no) Difenylazetidinonderivater, fremgangsmåte for deres fremstilling, legemidler som inneholder disse forbindelsene samt deres anvendelse
DK0751129T6 (da) Substituerede dihydrodibenzo(b,f)azepiner, fremgangsmåde til fremstilling deraf, deres anvendelse i behandlingen af nogle lidelser i centralnervesystemet og farmaceutiske sammensætninger indeholdende disse
NO20043819L (no) Topiramatsalter og preparater omfattende disse samt fremgangsmate og fremstilling for bruk derav
NO20024175D0 (no) Azetidinderivater, deres fremstilling og farmasöytiske forbindelser inneholdende de samme
IS8267A (is) [1,8]naftýridín-2-ón og tengd efnasambönd til notkunar við meðferð á geðklofa
NO20010277D0 (no) Benzocykloheptener, fremgangsmåte for fremstilling derav, farmasöytiske preparater inneholdende disse, og deres anvendelse for fremstilling av medikamenter
NO20025357D0 (no) Antranylamider og deres anvendelse som legemidler
DK1282616T3 (da) Hydroxyphenylpiperidin-4-ylidenmethylbenzamidderivater til behandling af smerter
DK1228028T3 (da) Hydroxyicosatetraenoatsalte, præparater og fremgangsmåder til anvendelse til behandling af öjentörhedslidelser
DK1432417T3 (da) Substituerede imidazolforbindelser og deres anvendelse til behandling af cancer
IS7266A (is) Lyfjaform sem innihalda sýru-óþolin virk efni og aðferðir til tilreiðslu þeirra
DK2083007T3 (da) Tiotropiumsalte, fremgangsmåder til deres fremstilling og lægemiddelformuleringer indeholdende disse
DK1381382T3 (da) Fremgangsmåder og præparater til behandling af öjensygdomme
NO20022022L (no) N-guanidinoalkylamider, deres fremstilling, deres anvendelse og farmasöytiske preparater omfattende disse
DK1098891T3 (da) Polycycliske thiazolidin-2-yliden-aminer, fremgangsmåde til fremstilling deraf og deres anvendelse som lægemidler
DK2067779T3 (da) Tiotropiumsalte, fremgangsmåde til deres fremstilling og lægemiddelformuleringer indeholdende disse